Insight: Cancer drugs proving worth earlier in testing:
"It typically has taken a decade and $1 billion to bring a new treatment to market.
But in the last two years a handful of cancer drugs - including Onyx Pharmaceutical
Inc's Kyprolis for multiple myeloma, Roche's Zelboraf for melanoma, and Pfizer's
Xalkori - were approved in about half that time because of improved genetic
screening, more definitive Phase I trials and the dire need for new, effective
treatments."
See:
http://news.yahoo.com/insight-cancer...--finance.html